Santarus, Inc. (SNTS) Tops Q3 EPS by 3c, Raises Guidance
Tweet
Share
E-mailGet Alerts SNTS Hot Sheet
Join SI Premium – FREE
Santarus, Inc. (NASDAQ: SNTS) reported Q3 EPS of $0.13, $0.03 better than the analyst estimate of $0.10. Revenue for the quarter came in at $54.7 million versus the consensus estimate of $52.95 million.
Santarus, Inc. sees FY2012 revenue of $210 million, versus prior guidance of $200 million and street estimates of $205.76 million.
Financial Outlook for 2012
Santarus has raised its revenue, net income and adjusted EBITDA outlook for the full year in 2012. The revised estimates are:
Total revenues of approximately $210 million, compared to its prior estimate of at least $200 million.
Net income guidance of approximately $12 million to $14 million, up from its prior estimate of $8 million to $11 million, which includes the impact of the approximately $4 million success-based regulatory milestone expense in the first quarter related to UCERIS and a $10 million expense for the success-based milestone for RUCONEST mentioned above.
Adjusted EBITDA guidance of approximately $29 million to $32 million, up from its prior estimate of $24 million to $29 million.
Santarus estimates expenses for the full year in 2012 as follows:
License fee expenses will include a $10 million milestone payable to Pharming in the fourth quarter of 2012 due to the successful completion of the Phase III clinical study for RUCONEST in treating acute attacks of HAE; and
The R&D expense estimate is lowered to approximately $27 million to $29 million from the prior estimate of $28 million to $30 million based on current projections for enrollment in the UCERIS Phase IIIb clinical study.
For earnings history and earnings-related data on Santarus, Inc. (SNTS) click here.
Santarus, Inc. sees FY2012 revenue of $210 million, versus prior guidance of $200 million and street estimates of $205.76 million.
Financial Outlook for 2012
Santarus has raised its revenue, net income and adjusted EBITDA outlook for the full year in 2012. The revised estimates are:
Total revenues of approximately $210 million, compared to its prior estimate of at least $200 million.
Net income guidance of approximately $12 million to $14 million, up from its prior estimate of $8 million to $11 million, which includes the impact of the approximately $4 million success-based regulatory milestone expense in the first quarter related to UCERIS and a $10 million expense for the success-based milestone for RUCONEST mentioned above.
Adjusted EBITDA guidance of approximately $29 million to $32 million, up from its prior estimate of $24 million to $29 million.
Santarus estimates expenses for the full year in 2012 as follows:
License fee expenses will include a $10 million milestone payable to Pharming in the fourth quarter of 2012 due to the successful completion of the Phase III clinical study for RUCONEST in treating acute attacks of HAE; and
The R&D expense estimate is lowered to approximately $27 million to $29 million from the prior estimate of $28 million to $30 million based on current projections for enrollment in the UCERIS Phase IIIb clinical study.
For earnings history and earnings-related data on Santarus, Inc. (SNTS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- Northrim BanCorp (NRIM) Tops Q1 EPS by 54c
- Core Laboratories (CLB) Misses Q1 EPS by 13c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
